GB8824709D0 - Oral dosage forms of omega-3 polyunsaturated acids - Google Patents

Oral dosage forms of omega-3 polyunsaturated acids

Info

Publication number
GB8824709D0
GB8824709D0 GB888824709A GB8824709A GB8824709D0 GB 8824709 D0 GB8824709 D0 GB 8824709D0 GB 888824709 A GB888824709 A GB 888824709A GB 8824709 A GB8824709 A GB 8824709A GB 8824709 D0 GB8824709 D0 GB 8824709D0
Authority
GB
United Kingdom
Prior art keywords
omega
dosage forms
oral dosage
polyunsaturated acids
polyunsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB888824709A
Other versions
GB2223943A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
Original Assignee
Tillotts Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma AG filed Critical Tillotts Pharma AG
Priority to GB8824709A priority Critical patent/GB2223943A/en
Publication of GB8824709D0 publication Critical patent/GB8824709D0/en
Priority to CA 2000881 priority patent/CA2000881A1/en
Priority to AU44856/89A priority patent/AU4485689A/en
Priority to PCT/GB1989/001251 priority patent/WO1990004391A1/en
Publication of GB2223943A publication Critical patent/GB2223943A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB8824709A 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids Withdrawn GB2223943A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids
CA 2000881 CA2000881A1 (en) 1988-10-21 1989-10-17 Oral dosage forms of omega-3 polyunsaturated acids
AU44856/89A AU4485689A (en) 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids
PCT/GB1989/001251 WO1990004391A1 (en) 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids

Publications (2)

Publication Number Publication Date
GB8824709D0 true GB8824709D0 (en) 1988-11-30
GB2223943A GB2223943A (en) 1990-04-25

Family

ID=10645593

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8824709A Withdrawn GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids

Country Status (4)

Country Link
AU (1) AU4485689A (en)
CA (1) CA2000881A1 (en)
GB (1) GB2223943A (en)
WO (1) WO1990004391A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
FR2663222A1 (en) * 1990-06-13 1991-12-20 Medgenix Group Sa OILY LIQUID MICROCAPSULE.
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
WO1997021434A1 (en) * 1995-12-11 1997-06-19 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (en) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh Oral dosage form containing CO-3-unsaturated fatty acids
JPWO2002102364A1 (en) * 2001-06-18 2004-09-30 山田　幸子 PPARγ agonistic pharmaceutical composition
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
AU2004216856A1 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
MX2008008171A (en) 2005-12-21 2008-11-12 Brudy Technology S L Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage.
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US8933255B2 (en) * 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
BRPI1007518A2 (en) 2009-02-10 2018-02-20 Amarin Pharma, Inc. use of ethyl ester eicopentanoic acid for treatment of hypertriglyceridemia
BRPI1011876B1 (en) 2009-04-29 2020-03-31 Amarin Pharma, Inc. STABLE PHARMACEUTICAL COMPOSITIONS UNDERSTANDING EICOSAPENTAENOIC ETHYLACID (ETHYL-EPA) AND USE OF THE SAME TO TREAT OR PREVENT A CARDIOVASCULAR DISEASE
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK2443246T3 (en) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ie Ltd COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY
RU2012116079A (en) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи PHARMACEUTICAL COMPOSITION, INCLUDING OMEGA-3 FATTY ACID AND HYDROXY DERIVATED STATIN AND WAYS OF ITS APPLICATION
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
RU2664429C2 (en) 2012-01-06 2018-08-17 Омтера Фармасьютикалс, Инк. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
EP4342546A3 (en) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6018712B2 (en) * 2014-04-25 2016-11-02 株式会社山田養蜂場本社 Absorption accelerator for unsaturated fatty acids
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (en) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (en) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the risk of cardiovascular events in a subject
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
SE8604117D0 (en) * 1986-09-29 1986-09-29 Kabivitrum Ab COMPOSITION

Also Published As

Publication number Publication date
CA2000881A1 (en) 1990-04-21
WO1990004391A1 (en) 1990-05-03
AU4485689A (en) 1990-05-14
GB2223943A (en) 1990-04-25

Similar Documents

Publication Publication Date Title
GB8824709D0 (en) Oral dosage forms of omega-3 polyunsaturated acids
HU891084D0 (en) Process for manufacturing of pharmaceutical compositions containing antiviricid and antibactericid fatty acids and monoglycerides
HUP9900337A3 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
ZA895512B (en) Fatty acid composition
EP0334154A3 (en) Method for the continiuous esterification of fatty acids
IL78528A0 (en) Difluoro-naphthyridine-and trifluoro-quinoline-carboxylic acids and esters and salts thereof and pharmaceutical compositions containing them
ZA855264B (en) Bisphosphonic acids and pharmaceutically acceptable salts and esters thereof
NZ216971A (en) Phosphonate esters and pharmaceutical compositions
NZ215622A (en) Enhanced-absorption drug compositions containing fatty acids, monoglycerides and lysophosphatidyl choline
GB8812653D0 (en) Pharmaceutical composition based on high concentration esters of docosahexaenoic acid
IL78533A0 (en) Esters of 2-diazo-3-siloxyalkenoic acids and their preparation
GB2172597B (en) Polymerisation of fatty acids
IL87185A (en) Preparation of quinolone- carboxylic acids
IL85776A0 (en) Pharmaceutical compositions comprising certain algae and polyunsaturated fatty acids and their preparation
EP0227301A3 (en) Process for the preparation of n-formyl-alpha-l-aspartyl-l-phenylalanine methyl ester
GB8529199D0 (en) Preparation of oxo-alkanedioic acids
ZA936233B (en) Method for the safe administration of fatty acids
ZA895758B (en) Polyunsaturated fatty acids
DE3660808D1 (en) Stabilized iodine fats and process for their preparation
GB2173190B (en) Disproportionation of unsaturated acids
GB8410625D0 (en) Conjugated polyunsaturated fatty acids
EP0226544A3 (en) Derivatives of alkyl-bicycloû2.2.1¨hept-5-ene-2-carboxylic acids
GB2183635B (en) Glyceride ester of gamma-linolenic acid
GB8712476D0 (en) Polyunsaturated fatty acids
GB2212048B (en) New unsaturated 3-benzylidenecamphor derivatives and their preparation

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)